Autologous Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics

Drug Profile

Autologous Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics

Alternative Names: Autologous ATA188; Autologous Epstein-Barr virus-specific T-cell therapy - Atara Biotherapeutics; EBV-CTL - Atara Biotherapeutics

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator Memorial Sloan-Kettering Cancer Center
  • Developer QIMR Berghofer Medical Research Institute
  • Class T lymphocyte cell therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Multiple sclerosis

Most Recent Events

  • 20 Apr 2017 Efficacy data from a phase I trial in Multiple sclerosis presented at the 69th Annual Meeting of the American Academy of Neurology (AAN-2017)
  • 09 Mar 2017 Atara Biotherapeutics plans to initiate a phase I trial of ATA 188 in Multiple sclerosis in the second half of 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top